嘉事堂复牌涨3.78% 同仁堂14.6亿拿下控股权

Core Viewpoint - The stock price of Jiasitang resumed trading on February 4, with a price of 17.02 yuan per share, reflecting a 3.78% increase and a total market capitalization of 4.962 billion yuan. The company announced a share transfer agreement with Tongrentang Group, which will change its controlling shareholder and actual controller to the Beijing Municipal Government State-owned Assets Supervision and Administration Commission [1]. Company Overview - Jiasitang Pharmaceutical Co., Ltd. was established in 1997 and listed on the Shenzhen Stock Exchange in 2010. It became part of the Everbright system in 2018 and serves as a major platform for Everbright's health business. The company's main operations include sales to secondary and tertiary hospitals, community medical centers, logistics distribution, and chain retailing, covering pharmaceuticals, biological products, medical devices, and traditional Chinese medicine [2]. Financial Performance - In the first half of 2025, Jiasitang achieved a revenue of 9.699 billion yuan and a net profit of 163 million yuan. The company is a leading pharmaceutical distributor in Beijing, serving over 300 secondary and tertiary hospitals with a coverage rate of 99%. In the medical device sector, Jiasitang has a strong channel and terminal network in high-value consumables, focusing on regions such as the Yangtze River Delta, Guangdong-Hong Kong-Macau Greater Bay Area, Beijing-Tianjin-Hebei, Southwest, and Northwest, establishing sales channels with over 2,100 hospitals [3]. Retail Operations - Jiasitang's retail pharmacies cover multiple areas in Beijing, with some stores collaborating with top-tier hospitals to provide "dual-channel" pharmaceutical services [4].